A single-center retrospective study evaluating 113 solid-organ transplant recipients with diabetes found substantial rates of kidney impairment and above-target glycemia, alongside notable baseline differences between individuals with pretransplant diabetes mellitus and post-transplant diabetes mellitus. Assessed at an outpatient index visit between May 2017 and May 2026, the overall patient cohort exhibited a mean estimated glomerular filtration rate of 60.77 ± 28.39 mL/min/1.73 m² and a mean glycated hemoglobin of 7.40 ± 1.84%. Nearly half of the participants presented with diminished renal function, with 49.5% recording an estimated glomerular filtration rate below 60 mL/min/1.73 m², while 53.2% displayed glycated hemoglobin levels exceeding 7% at their single cross-sectional assessment.
Diabetes is recognized as a major contributor to morbidity following solid-organ transplantation, yet clinical comparisons examining renal function and glycemic control between pretransplant diabetes mellitus and post-transplant diabetes mellitus have remained limited in medical literature. This gap in evidence is especially pronounced for cohorts in which most recipients have received an organ other than a kidney. To evaluate these dynamics, researchers analyzed cross-sectional outpatient records to describe kidney function, albuminuria, glycemic control, and medical treatment patterns, establishing the primary comparison between pretransplant and post-transplant diabetes alongside secondary exploratory assessments.
The investigated cohort consisted predominantly of non-kidney organ recipients, comprising 51.3% liver transplant recipients, 36.3% kidney transplant recipients, and 12.4% heart transplant recipients. Within this group, post-transplant diabetes mellitus was diagnosed in 61.6% of patients. Across the entire sample, the median time elapsed since transplantation was 9 years, with an interquartile range spanning from 5 to 16 years. Albuminuria, defined by a urinary albumin-to-creatinine ratio of 30 mg/g or greater, was identified in 45.9% of the 98 patients who had an available urinary measurement, demarcating a high-risk subgroup under Kidney Disease: Improving Global Outcomes criteria.
Marked differences emerged when comparing patients based on the timing of diabetes onset. Recipients with pretransplant diabetes had survived a significantly shorter median time since their transplant procedure compared to those with post-transplant diabetes, recording 6.0 years versus 11.0 years. Patients with pretransplant diabetes were also nominally older, presenting a median age of 64.0 years compared with 60.0 years in the post-transplant group. Furthermore, recipients with pretransplant diabetes displayed a lower unadjusted mean estimated glomerular filtration rate of 53.06 ± 21.82 mL/min/1.73 m², compared to 65.78 ± 31.02 mL/min/1.73 m² in those who developed diabetes post-transplantation.
Categorical distributions of renal impairment highlighted this disparity, as patients with pretransplant diabetes were significantly more likely to fall into estimated glomerular filtration rate categories G3 through G5, encompassing 68.3% of pretransplant cases compared to 37.3% of post-transplant cases. In contrast to renal filtration measures, glycemic regulation showed remarkable parity between the cohorts, as no statistically significant difference in glycated hemoglobin was detected between pretransplant and post-transplant diabetes groups. Urinary albumin-to-creatinine ratios also demonstrated no statistically significant difference between diabetes groups once multiple testing adjustments were applied via Holm and Benjamini–Hochberg procedures.
To evaluate potential confounding factors, the investigative team specified sequential multivariable linear regression models founded upon an explicit causal framework. In Model 1 unadjusted analyses, filtration differences favored the post-transplant cohort. In Model 2, which adjusted for age, sex, transplanted organ type, and time elapsed since transplantation, the estimated glomerular filtration rate remained 12.7 mL/min/1.73 m² higher among recipients with post-transplant diabetes. However, in Model 3, which added further statistical adjustments for body mass index, glucocorticoid therapy, and calcineurin-inhibitor exposure, this difference attenuated to 7.8 mL/min/1.73 m² with a 95% confidence interval of −4.9 to 20.5 mL/min/1.73 m².
Sensitivity evaluations that excluded kidney transplant recipients altered the magnitude of these mathematical associations. In the non-kidney subcohort, the unadjusted estimated glomerular filtration rate difference between post-transplant and pretransplant diabetes widened to 19.2 mL/min/1.73 m² with a 95% confidence interval of 6.6 to 31.7 mL/min/1.73 m². When applying the covariates of Model 2 to this non-kidney group, the estimated filtration advantage for post-transplant diabetes attenuated to 10.5 mL/min/1.73 m² with a 95% confidence interval crossing zero, spanning −3.1 to 24.0 mL/min/1.73 m².
Exploratory analyses within the study identified critical therapeutic and biochemical patterns across the recipient population. In an exploratory regression model, low-density lipoprotein cholesterol was positively associated with the urinary albumin-to-creatinine ratio, demonstrating a 1.20-fold increase per 10 mg/dL. Regarding contemporary pharmacotherapy, only 40% of the transplant recipients presenting with albuminuria were receiving a sodium-glucose cotransporter 2 inhibitor. Additionally, secondary comparisons conducted between early-onset and late-onset post-transplant diabetes revealed no statistically significant differences in renal function or glycemic control, although the authors noted that confidence intervals for these subgroup estimates were wide.
The study authors concluded that solid-organ transplant recipients with diabetes frequently exhibit reduced filtration rates, albuminuria, and glycated hemoglobin levels above clinical targets when assessed years after transplantation. Because reduced filtration was often non-albuminuric, albuminuria identified a distinct high-risk subgroup that remained undertreated with sodium-glucose cotransporter 2 inhibitors. Furthermore, the lower estimated filtration in pretransplant diabetes was not explained by age, sex, organ type, or post-transplant duration, but attenuated after accounting for body mass index and immunosuppressive exposure; consequently, the observed disparities reflect two differently selected populations influenced by survivorship and prevalent-user selection rather than an intrinsic biological effect of diabetes category.
Subject of Research: Kidney function and glycemic control in solid-organ transplant recipients with pretransplant versus post-transplant diabetes
Article Title: Kidney function and glycemic control in solid-organ transplant recipients with pretransplant versus post-transplant diabetes: a cross-sectional study of a predominantly non-kidney transplant cohort
Article References: Batista Ferreira, H., Bernardes Izza, L., Gonçalves Duarte, A., Farias, E., Yamashita, Y. P., Ensser, I. R., & Lauria, M. W. (2026). Kidney function and glycemic control in solid-organ transplant recipients with pretransplant versus post-transplant diabetes: a cross-sectional study of a predominantly non-kidney transplant cohort. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/s13098-026-02359-x
Image Credits: AI Generated
DOI: 10.1186/s13098-026-02359-x
Keywords: solid-organ transplantation, pretransplant diabetes mellitus, post-transplant diabetes mellitus, kidney function, estimated glomerular filtration rate, glycemic control, HbA1c, albuminuria, urinary albumin-to-creatinine ratio, liver transplantation, kidney transplantation, heart transplantation, SGLT2 inhibitors, calcineurin inhibitors, glucocorticoids, KDIGO risk, LDL cholesterol, cross-sectional study
News Source: Jerry Hayes. (November 21, 2026). Kidney Function Differs by Diabetes Onset Timing Across Solid Organ Transplants. Scienmag.



